Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients

A Phase II Trial Pemetrexed Carboplatin as First Line Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) in Elderly Patients

A phase II study to evaluate the efficacy and safety profile of the combination of Pemetrexed and Carboplatin in elderly patients with advanced non-small cell lung cancer

Inclusion Criteria:

• Pathologically confirmed Non Small Cell Lung Cancer Stage IIIb (not amenable to radiotherapy treatment) or Stage IV
• No previous chemotherapy for lung cancer
• Men and women > or = 70 years
• At least one uni-dimensionally measurable lesion (Response Evaluation Criteria In Solid Tumors [RECIST]criteria)
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1

Exclusion Criteria:

• Treatment within the last 30 days with a drug that has not received regulatory approval
• Serious systemic disorders
• Inability to discontinue administration of aspirin or anti-inflammatory non steroid
• Concurrent administration of any other antitumor therapy
• Brain metastasis